Skip to main content
Premium Trial:

Request an Annual Quote

And Covered

Google will be covering cancer DNA testing as part of its employee benefits plan beginning in January, Foundation Medicine' President and CEO Michael Pellini noted during a conference call.

As GenomeWeb Daily News reports, Google employees and their family members who have cancer will have covered access to Foundation Medicine's FoundationOne and FoundationOne Heme tests. These tests can cost between $5,800 and $7,200, Reuters adds, and help tailor cancer treatment.

It notes that Google Ventures, the company's venture capital and investment arm, has invested in Foundation Medicine and that Google Ventures' Krishna Yeshwant is on Foundation Medicine's board.

Valleywag says that as tech companies compete for talented developers there is a "never-ending game of perk one-upsmanship."

"This latest offering could be a sign of more perks to come, given Google's recent emphasis on healthcare and genetic data and the regulators who get in the way, it adds.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.